Search

852 Result(s)
Sort by

Biberach

Biberach

The largest research and development center of Boehringer Ingelheim is located in Biberach, Germany.
Boehringer Ingelheim partners with PetMedix

Boehringer Ingelheim partners with PetMedix

Partnering with PetMedix on Ky9™ platform cutting edge technology as a means to bring innovative new therapies to improve health of animals
Rabies? Not in Mexico!

Rabies? Not in Mexico!

Mexico has been a rabies-free country for the last five years. How does Mexico achieve this? Learn how we're collaborating in this fight against rabies.
The big, the bold, and the few

The big, the bold, and the few

In the animal health industry, fewer players are vying for bigger market shares. What does that mean for companies, veterinarians, and consumers?
Boehringer Ingelheim Access to Healthcare Strategy 2025

Boehringer Ingelheim Access to Healthcare Strategy 2025

Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach.
Cardiometabolic Diseases

Cardiometabolic Diseases

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.
Fast-Track-Designation-NASH

Fast-Track-Designation-NASH

Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
Patient Organizations

Patient Organizations

Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.
Partnering pet therapeutics

Partnering pet therapeutics

Learn more about our research focus and our most recent partnerships regarding pet therapeutics.
Our evolved employer value proposition

Our evolved employer value proposition

Find out from a father-daughter duo how we live up to our people promise and how our company identifies itself and differentiates from other employers.
InPedILD_trial_enrollment

InPedILD_trial_enrollment

First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
Expectations towards our business partners

Expectations towards our business partners

We utilize an extensive network of international suppliers for procuring raw materials, intermediates, packaging materials, technical components and services to deliver our innovative medications worldwide.
Access to Healthcare Strategy Innovation

Access to Healthcare Strategy Innovation

Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.